Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study

BACKGROUND: Adjuvant tamoxifen therapy approximately halves the risk of recurrence in estrogen receptor-positive (ER+) breast cancer patients, but many women respond insufficiently to therapy. Expression of multi-drug resistance protein 2 (MRP2) in breast cancer may potentiate tamoxifen resistance....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Acta Oncol
Glavni autori: Hjorth, Cathrine F., Nielsen, Anja S., Sørensen, Henrik T., Lash, Timothy L., Damkier, Per, Hamilton-Dutoit, Stephen, Cronin-Fenton, Deirdre
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6526175/
https://ncbi.nlm.nih.gov/pubmed/30458661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/0284186X.2018.1537508
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items